Table 3.

Cellular parameters in treatment and placebo groups

Soy group (n = 49)Placebo group (n = 49)Between group
ParameterEntrySix moPEntrySix moPDifferenceP
Median Ki-67 labeling index (interquartile range)
 All subjects981.17 (0.66–1.93)1.09 (0.75–2.33)0.820.97 (0.70–1.90)0.92 (0.59–1.96)0.14−0.03 (−0.42 to 0.08)0.24
 Postmenopausal450.63 (0.52–1.08)0.77 (0.35–0.94)0.560.70 (0.57–1.07)0.63 (0.42–0.98)0.22−0.12 (−0.37 to 0.23)0.73
 Premenopausal531.71 (1.12–2.35)2.18 (1.18–3.04)0.041.90 (0.88–2.33)1.94 (0.92–2.55)0.560.19 (−0.46 to 1.07)0.31
Proportion of women with atypical cytology
 All subjects9842.9%53.1%0.4240.8%53.1%0.31−2.1%0.83
 Postmenopausal4533.3%23.8%0.7333.3%33.3%0.99−9.5%0.72
 Premenopausal5350.0%75.0%0.1048.0%72.0%0.151.0%0.99
Median Masood score (interquartile range)
 All subjects9814.0 (13.0–15.0)14.0 (12.0–15.0)0.6813.0 (13.0–15.0)14.0 (13.0–15.0)0.370.0 (−1.0 to 1.0)0.64
 Postmenopausal4514.0 (13.0–15.0)13.0 (12.0–14.0)0.0413.0 (13.0–14.5)13.0 (12.0–15.0)0.320.0 (−1.0 to 0.0)0.15
 Premenopausal5314.0 (13.0–15.5)15.0 (14.0–16.0)0.3314.0 (13.0–16.0)15.0 (14.0–16.0)0.131.0 (−1.0 to 2.0)0.41
Atypical features on spectral imaging (interquartile range)
 All subjects940.42 (0.15–0.60)0.32 (0.10–0.58)0.500.42 (0.15–0.60)0.51 (0.19–0.72)0.630.02 (−0.28 to 0.23)0.47
 Postmenopausal430.41 (0.10–0.51)0.38 (0.08–0.56)0.570.40 (0.12–0.56)0.29 (0.14–0.58)0.700.04 (−0.21 to 0.24)0.81
 Premenopausal510.47 (0.23–0.66)0.28 (0.10–0.60)0.290.45 (0.18–0.75)0.62 (0.28–0.77)0.660.00 (−0.30 to 0.21)0.32